Page 775 - Read Online

Page 10 of 15 Correnti et al. Hepatoma Res 2018;4:69 I http://dx.doi.org/10.20517/2394-5079.2018.96

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
2. Oikawa T. Cancer stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology 2016;64:645-51.
3. Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer
to personalized medicine? Cell Biosci 2011;1:5.
4. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.
5. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, et al. Expert consensus document: cholangiocarcinoma: current knowledge
and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev
Gastroenterol Hepatol 2016;13:261-80.
6. Machida K. Existence of cancer stem cells in hepatocellular carcinoma: myth or reality? Hepatol Int 2017;11:143-7.
7. Sia D, Llovet JM. Liver cancer: translating ‘-omics’ results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol
Hepatol 2017;14:571-2.
8. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol 2015;62:S144-56.
9. Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer
Cell Int 2018;18:44.
10. Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in hepatocellular carcinoma: facing the challenges. Liver Cancer 2016;5:128-38.
11. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, et al. Genomic and genetic characterization of cholangiocarcinoma identifies
therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021-31.e15.
12. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21.
13. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215-29.
14. Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis
Model Mech 2013;6:281-92.
15. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.
16. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol
2011;8:512-22.
17. Govaere O, Wouters J, Petz M, Vandewynckel YP, Van den Eynde K, et al. Laminin-332 sustains chemoresistance and quiescence as part of
the human hepatic cancer stem cell niche. J Hepatol 2016;64:609-17.
18. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004;24:127-37.
19. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting
hepatic progenitor cell origin. Hepatology 2008;47:1544-56.
20. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from
hepatic progenitor cells. Nat Med 2006;12:410-6.
21. Nomoto K, Tsuneyama K, Cheng C, Takahashi H, Hori R, et al. Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently
expressed p63-positive basal/stem-cell phenotype. Pathol Res Pract 2006;202:71-6.
22. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/
progenitor cell features. Gastroenterology 2009;136:1012-24.
23. Zhou H, Wang H, Zhou D, Wang Q, Zou S, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma
may hold common disease process for carcinogenesis. Eur J Cancer 2010;46:1056-61.
24. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both
hepatocytic and cholangiocytic differentation. Hepatology 2018;68:113-26.
25. Sato K, Marzioni M, Meng F, Francis H, Glaser S, et al. Ductular reaction in liver diseases: pathological mechanisms and translational
significances. Hepatology 2018; doi: 10.1002/hep.30150.
26. Gouw AS, Clouston AD, Theise ND. Ductular reactions in human liver: diversity at the interface. Hepatology 2011;54:1853-63.
27. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, et al. The hepatic stem cell niche: identification by label-retaining cell
assay. Hepatology 2008;47:1994-2002.
28. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, et al. The canals of Hering and hepatic stem cells in humans. Hepatology
1999;30:1425-33.
29. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-22.